Future studies will focus on the in vivo therapeutic effect of such nanonutraceuticals to inhibit DPP-IV and ACE and test their behavior to modulate the cholesterol metabolism pathway for targeting the metabolic diseases. Here, ACE is linked to metabolic disease.